Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL-Reference-Cited by-同舟云学术

Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL

Published:2023-11-15 Issue:22 Volume:7 Page:6844-6849
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Blumenberg Viktoria¹²³⁴^ORCID,Busch Galina²,Baumann Stephan²^ORCID,Jitschin Regina⁵⁶,Iacoboni Gloria⁷⁸^ORCID,Gallur Laura⁷⁸^ORCID,Iraola-Truchuelo Josu⁷^ORCID,Hoster Eva¹⁹^ORCID,Winkelmann Michael¹⁰,Hellwig Konstantin¹¹^ORCID,Schmidt Christian¹,Frölich Lisa¹³,Tast Benjamin²,Hildebrand Friederike¹,Rejeski Kai¹²³⁴,Dekorsy Franziska¹²,Schmidkonz Christian⁴¹³¹⁴,Bäuerle Tobias¹¹,Kunz Wolfgang G.¹⁰^ORCID,Mougiakakos Dimitrios⁵⁶¹⁵^ORCID,Müller Fabian⁵¹⁵^ORCID,von Bergwelt-Baildon Michael¹³⁴,Barba Pere⁷⁸,Bücklein Veit L.¹²⁴^ORCID,Mackensen Andreas⁵¹⁵^ORCID,Völkl Simon⁵¹⁵,Subklewe Marion¹²³⁴^ORCID

Affiliation:

1. 1Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany

2. 2Laboratory for Translational Cancer Immunology, LMU Gene Center, LMU Munich, Munich, Germany

3. 3German Cancer Consortium (DKTK), partner site Munich, Munich, Germany

4. 4Bavarian Center for Cancer Research (BZKF), partner site Munich, Munich, Germany

5. 5Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany

6. 6Department for Hematology and Oncology, Otto-von-Guericke University, Magdeburg, Germany

7. 7Department of Hematology, Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain

8. 8Department of Medicine, Universitat Autònoma of Barcelona, Barcelona, Spain

9. 9Institute for Medical Informatics, Biometry and Epidemiology, LMU Munich, Munich, Germany

10. 10Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany

11. 11Department of Radiology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany

12. 12Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany

13. 13Department of Nuclear Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany

14. 14Institute for Medical Engineering, University of Applied Sciences Amberg-Weiden, Weiden, Germany

15. 15Bavarian Cancer Research Center (BZKF), partner site Erlangen, Erlangen, Germany

Publisher

American Society of Hematology

Subject

Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/7/22/6844/2109120/blooda_adv-2023-010364-main.pdf

Reference23 articles.

1. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany;Bethge;Blood,2022

2. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium;Nastoupil;J Clin Oncol,2020

3. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma;Iacoboni;Blood Adv,2022

4. Value of CT-textural features and volume-based PET parameters in comparison to serologic markers for response prediction in patients with diffuse large B-cell lymphoma undergoing CD19-CAR-T cell therapy;Reinert;J Clin Med,2022

5. Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy;Iacoboni;Ann Hematol,2021

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of bendamustine‐containing bridging therapy in R/R LBCL patients receiving CD19 CAR T‐cells;HemaSphere;2024-06-26

2. CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity;Blood Advances;2024-06-25

3. CAR T-cell expansion: harmful or helpful?;Blood Advances;2024-06-25

4. Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients;Blood Cancer Journal;2024-05-17

5. CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis;The Lancet;2024-04